WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia

References

• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Marková J, Marková J, Trnková Z, et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma 2009;50:1448–1460.
   PubMed Web of Science ®Google Scholar
• Santamaría CM, Chillón MC, García-Sanz R, et al. Molecular stratification model for prognosis in cytogeneticallynormal acute myeloid leukemia. Blood 2009; 114:148–152.
   PubMed Web of Science ®Google Scholar
• Santamaría C, Chillón MC, García-Sanz R, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 2010;89:453–458.
   PubMed Web of Science ®Google Scholar
• Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009;114:2386–2392.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Krauter J, et al.; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimalresidual disease in acute leukemia. Blood 1994;84:3071–3079.
   PubMed Web of Science ®Google Scholar
• Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639–643.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Maurer U, Weidmann E, et al. Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 1997;25:435–443.
   PubMed Web of Science ®Google Scholar
• Barragán E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926–933.
   PubMed Web of Science ®Google Scholar
• Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49–59.
   PubMed Web of Science ®Google Scholar
• Noronha SA, Farrar JE, Alonzo TA. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;53:1136–1139.
   PubMed Web of Science ®Google Scholar
• Rodrigues PC, Oliveira SN, Viana MB, et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatric Blood Cancer 2007;49:133–138.
   PubMed Web of Science ®Google Scholar
• Visani G, Petti MC, Cenacchi A, et al. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymphoma 1995;19:447–451.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real time’ quantitative reverse transcriptions polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia: a Europe Against Cancer program. Leukemia 2003;17:2318–2357.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukaemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326–4335.
   PubMed Web of Science ®Google Scholar
• Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:976–982.
   PubMed Web of Science ®Google Scholar
• Scholl S, Fricke HJ, Sayer HG, Höffken K. Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 2009;135:491–505.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009:385–395.
   PubMedGoogle Scholar
• Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596–604.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Ammatuna E, Serena S, et al. The genotypenucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. Br J Haematol 2010;149:383–387.
   PubMed Web of Science ®Google Scholar
• Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:3622–3626.
   PubMed Web of Science ®Google Scholar
• Gupta V, Chun K, Yi Q-L, et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005;103:2082–2090.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Estey E. AML in older patients: are we making progress? Best Pract Res Clin Haematol 2009;22:529–536.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116:4422–4429.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005;19:1345–1349.
   PubMed Web of Science ®Google Scholar
• Mead AJ, Gale RE, Hills RK, et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008;112:444–445.
   PubMed Web of Science ®Google Scholar
• Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmatic/mutated nucleophosmin (NPMc+AML): biological and clinical features. Blood 2007;109:874–885.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Miething C, Maurer U, et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217–1225.
   PubMed Web of Science ®Google Scholar
• Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639–643.
   PubMed Web of Science ®Google Scholar
• Lasa A, Carricondo M, Estivill C, et al. WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 2009;33:1643–1649.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195–5201.
   PubMed Web of Science ®Google Scholar
• Hohenstein P, Hastie ND. The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet 2006;15:196–201.
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868–876.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010;107:13824–13829.
   PubMed Web of Science ®Google Scholar
• King-Underwood L, Pritchard-Jones K. Wilms’ tumor (WT1)gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91: 2961–2968.
   PubMed Web of Science ®Google Scholar
• Summers K, Stevens J, Kakkas I, et al. Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007;21:550–551.
   PubMed Web of Science ®Google Scholar
• Virappane P, Gale R, Hills R, et al. Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008;26:5429–5435.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2008;26:4595–4602.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Moschny S, et al.; German-Austrian AML Study Group. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009;113:4505–4511.
   PubMed Web of Science ®Google Scholar
• Ho PA, Kuhn J, Gerbing RB, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol 2011;29:704–711.
   PubMed Web of Science ®Google Scholar
• Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts afavorable outcome in patients with cytogenetically normalacute myeloid leukaemia. J Clin Oncol 2010;28:578–585.
   PubMed Web of Science ®Google Scholar
• Damm F, Heuser M, Morgan M, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011;117:4561–4568.
   PubMed Web of Science ®Google Scholar